Overview

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Epothilone B
Epothilones